M9317
Anti-MeCP2 antibody produced in rabbit
~0.6 mg/mL, affinity isolated antibody, buffered aqueous solution
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~75 kDa
species reactivity
human
concentration
~0.6 mg/mL
technique(s)
microarray: suitable
western blot: 0.5-1 μg/mL using nuclear extracts of the MCF7 breast carcinoma cell line.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... MECP2(4204)
mouse ... Mecp2(17257)
rat ... Mecp2(29386)
Related Categories
General description
Methyl-CpG binding protein 2 (MeCP2) possesses a methyl-CpG-binding domain (MBD) and a transcriptional repression domain.
Immunogen
synthetic peptide corresponding to the C-terminus of human MeCP2 (amino acids 465-478) conjugated to KLH. The sequence is conserved in rat and mouse.
Biochem/physiol Actions
MeCP2 can bind to a single symmetrically methylated CpG pair. It is also capable of binding to chromosomes at sites known to have methylated DNA. MeCP2 silences transcription by recruiting the histone deacetylase (HDAC) repressive machinery via recruitment of the Sin 3A corepressor thus removing acetyl groups from histones and consequently silencing genes.
Methyl-CpG binding protein 2 (MeCP2) has been shown be crucial for brain development. It is part of the methyl-CpG-binding proteins, which are involved in repression of gene expression by binding to methylated DNA. Mutations in the gene encoding MeCP2 have been associated with Rett syndrome (RTT).
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joseph R Kurian et al.
Epigenetics, 2(3), 173-178 (2007-10-30)
Pervasive developmental disorder is a classification covering five related conditions including the neurodevelopmental disorder Rett syndrome (RTT) and autism. Of these five conditions, only RTT has a known genetic cause with mutations in Methyl-CpG-binding protein 2 (MeCP2), a global repressor
Abdul Waheed Khan et al.
Epigenetics, 12(12), 1028-1037 (2018-02-08)
Although methyl CpG binding domain protein-2 (MeCP2) is commonly understood to function as a silencing factor at methylated DNA sequences, recent studies also show that MeCP2 can bind unmethylated sequences and coordinate gene activation. MeCP2 displays broad binding patterns throughout
The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation
Fuks F, et al.
Test, 278(6), 4035-4040 (2003)
David P Stuss et al.
Nucleic acids research, 41(9), 4888-4900 (2013-04-06)
MeCP2 is a methyl-CpG-binding protein that is a main component of brain chromatin in vertebrates. In vitro studies have determined that in addition to its specific methyl-CpG-binding domain (MBD) MeCP2 also has several chromatin association domains. However, the specific interactions
Romana Tomasoni et al.
eLife, 6 (2017-03-30)
Inflammation modifies risk and/or severity of a variety of brain diseases through still elusive molecular mechanisms. Here we show that hyperactivation of the interleukin 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service